Introduction {#Sec1}
============

Cervical cancer is the fourth most common cancer among women worldwide and the fourth leading cause of cancer-related deaths \[[@CR1]\]. Persistent human papillomavirus (HPV) infection, especially high-risk HPV (HR-HPV) infection, is the main cause of precancerous lesions and cervical cancer \[[@CR2], [@CR3]\], and is closely related to cervical and reproductive tract cancers \[[@CR4]\]. However, the prevalence of HPV infection remains at a high level in China. In China alone, it is estimated that 98,900 cervical cancer cases, accounting for approximately 20% of total new cases globally, and nearly 30,500 cervical cancer deaths occur each year \[[@CR5]\].

A meta-analysis made by Li et al. showed that the overall infection rate of HR-HPV in mainland Chinese women was 19.0% \[[@CR6]\] and the national overall prevalence of HPV infection was 15.54% \[[@CR7]\]. Some studies have investigated the HPV infection rate and the genotype distribution of Shanghai China in Minhang district \[[@CR8]\], female \[[@CR9]\] and male \[[@CR10]\] patients in the Songjiang district. Our study's purpose was to examine trends in HPV prevalence from 2011 to 2019 in the District Zhoupu of Shanghai City in China, among each 5- year age group, comparing prevalence rates.

Methods {#Sec2}
=======

Data source {#Sec3}
-----------

We extracted 59,541 women data on HPV prevalence in China at Shanghai Zhoupu Hospital from 2011 to 2019. The data is in the form of 5-year age groups. As a regional medical center, Shanghai Zhoupu Hospital provides medical and health services for about 500,000 people in nearby districts and towns.

Ethics statement {#Sec4}
----------------

This study was approved by the Institutional Medical Ethics Review Board of Zhoupu Hospital in Shanghai City. The participant received informed consent. For participants under the age of 18, the parents signed a consent form. Confidentiality was ensured during the data collection process at Zhoupu Hospital. Data is analyzed anonymously.

HPV genotyping {#Sec5}
--------------

By using Human papillomavirus (HPV) typing test kits (PCR + membrane hybridization) analysis, HPV genotyping was performed on the collected specimens. This assay has been approved by the Chinese FDA (Certification Number (2014): 3402188).

PCR membrane hybridization was used to detect 21 HPV genotypes (6,11,16,18,31,33,35,39,42,43,44,45,51,52,56,58,59,66,68 and 81) by reverse dot hybridization and envelope specific probe membrane hybridization. Sample collection and DNA extraction were the same as PCR fluorescence method. The PCR mix, Taq enzyme and DNA template were mixed in proportion with the typing test kit provided by China Chaozhou Hybribio biochemistry Co., Ltd. (Stock code: 300639.SZ). Amplification parameters were: 95 °C 9 min, 40 cycles (95 °C 20s, 55 °C 30s, 72 °C 30s), 72 °C 5 min. All outcomes were used in the hybridization process. After color rendering, the positive test results were clear blue and purple dots. According to the distribution of HPV types in membrane strips, the positive points were determined. Negative and positive control were set up in the whole process. Internal quality control and external quality assessment was taken in the experiment and the results met the requirements.

Statistical analysis {#Sec6}
--------------------

All HPV data from 2011 to 2019 were entered into an Excel spreadsheet and then analyzed on the R platform ([www.r-project.org](http://www.r-project.org)) (v3.2.0) and R packages, and the overall and type-specific prevalence of HPV were calculated. All genotypes from single and multiple infections were computed individually. These data were also stratified by age(\< 20 years, 20--24 years, 25--29 years,30--34 years, 35--39 years,40--44 years, 45--49 years, 50--54 years, 55--59 years, 60--64 years, 65--69 years,70--74 years, 75--79, years 80--84 years, ≥85 years). The HPV prevalence rate was estimated by a proportion and summarized as a percentage. The secular trends for HPV subtypes and for HPV infection rates of different ages were calculated using student t-test. *p* \< 0.05 was considered statistically significant.

Results {#Sec7}
=======

Characteristics of the study participants {#Sec8}
-----------------------------------------

In this study, a total of 59,541 women from Shanghai Zhoupu Hospital, underwent outpatient gynecological examinations and met the participation criteria. The ages of the participants were between 15 and 94 years. The mean age was 37.49. Among the 59,541 subjects, 10,670 women were positive for HPV infection, with a total HPV infection rate of 17.92% (10,670 / 59,541) and a HR-HPV positive rate of 15.56% (9263 / 59,541). Therefore, 86.81% of the infections were caused by HR-HPV.

The six most prevalent HR-HPV genotypes were HPV 52, 16, 58, 53, 39, and 51; however, the top three LR-HPV genotypes were HPV 81,6 and 11. (Table [1](#Tab1){ref-type="table"}). Table 1Single and multiple type infection rates of different HPV subtypes in District Zhoupu of Shanghai CityHPV subtypePositive, n(%)Single-type infection, n(%)Multiple-type infection, n (%)HPV522130 (3.58)1226 (2.06)904 (1.52)HPV161695 (2.85)1008 (1.69)687 (1.15)HPV581571 (2.64)822 (1.38)749 (1.26)HPV811155 (1.94)603 (1.01)552 (0.93)HPV531080 (1.81)551 (0.93)529 (0.89)HPV39871 (1.46)448 (0.75)423 (0.71)HPV51863 (1.45)448 (0.75)415 (0.7)HPV33762 (1.28)333 (0.56)429 (0.72)HPV6636 (1.07)293 (0.49)343 (0.58)HPV18603 (1.01)302 (0.51)301 (0.51)HPV68590 (0.99)305 (0.51)285 (0.48)HPV31575 (0.97)275 (0.46)300 (0.5)HPV11542 (0.91)249 (0.42)293 (0.49)HPV66494 (0.83)220 (0.37)274 (0.46)HPV56340 (0.57)161 (0.27)179 (0.3)HPV59238 (0.4)99 (0.17)139 (0.23)HPV44207 (0.35)107 (0.18)100 (0.17)HPV35173 (0.29)80 (0.13)93 (0.16)HPV45173 (0.29)85 (0.14)88 (0.15)HPV42137 (0.23)76 (0.13)61 (0.1)HPV4366 (0.11)26 (0.04)40 (0.07)

Trends of different HPV subtype infection rates {#Sec9}
-----------------------------------------------

Among these 21 HPV subtypes examined, HPV 52, 16, and 58 were also most commonly seen in women both with single-type and multiple-type HPV infections (Table [1](#Tab1){ref-type="table"}). Here, HPV subtype infection rate is calculated as the ratio of the number of HPV subtype infections to the total number of participants in this study (*N* = 59,541).

We investigated the temporal trend of HPV subtype infection. From 2011 to 2019, HPV16, 52, and 58 infection rates were higher. Except for HPV43, there are significant differences in secular trends for most HPV subtypes from 2011 to 2019 (*P* \< 0.05, Table [2](#Tab2){ref-type="table"}). Table 2Secular trends of different HPV subtype infection rates from 2011 to 2019HPV subtype2011,n(%)2012,n(%)2013,n(%)2014,n(%)2015,n(%)2016,n(%)2017,n(%)2018,n(%)2019,n(%)*P* value for trendHPV1658 (17.52)107 (13.21)181 (14.62)216 (10.34)240 (10.95)251 (10.87)378 (10.99)263 (10.59)1 (11.11)0.002HPV5257 (17.22)118 (14.57)178 (14.38)296 (14.18)317 (14.46)286 (12.38)482 (14.01)393 (15.83)3 (33.33)0.0029HPV5829 (8.76)110 (13.58)114 (9.21)228 (10.92)202 (9.22)258 (11.17)343 (9.97)286 (11.52)1 (11.11)0.003HPV8123 (6.95)58 (7.16)97 (7.84)177 (8.48)203 (9.26)225 (9.74)234 (6.8)137 (5.52)1 (11.11)0.0033HPV5321 (6.34)58 (7.16)75 (6.06)139 (6.66)164 (7.48)181 (7.84)243 (7.06)199 (8.01)0 (0)0.0012HPV1121 (6.34)39 (4.81)64 (5.17)77 (3.69)82 (3.74)67 (2.9)112 (3.26)80 (3.22)0 (0)0.0037HPV1819 (5.74)40 (4.94)54 (4.36)79 (3.78)96 (4.38)77 (3.33)133 (3.87)105 (4.23)0 (0)0.0022HPV617 (5.14)44 (5.43)52 (4.2)105 (5.03)105 (4.79)104 (4.5)118 (3.43)91 (3.66)0 (0)0.002HPV3115 (4.53)38 (4.69)68 (5.49)101 (4.84)72 (3.28)93 (4.03)122 (3.55)66 (2.66)0 (0)0.0022HPV3315 (4.53)68 (8.4)67 (5.41)139 (6.66)108 (4.93)117 (5.06)148 (4.3)100 (4.03)0 (0)0.0019HPV6613 (3.93)18 (2.22)37 (2.99)54 (2.59)76 (3.47)82 (3.55)118 (3.43)96 (3.87)0 (0)0.0047HPV6812 (3.63)26 (3.21)70 (5.65)89 (4.26)77 (3.51)81 (3.51)133 (3.87)102 (4.11)0 (0)0.0031HPV397 (2.11)26 (3.21)41 (3.31)112 (5.36)151 (6.89)166 (7.19)212 (6.16)156 (6.28)0 (0)0.0076HPV455 (1.51)7 (0.86)20 (1.62)29 (1.39)17 (0.78)30 (1.3)43 (1.25)20 (0.81)2 (22.22)0.0033HPV565 (1.51)20 (2.47)36 (2.91)41 (1.96)44 (2.01)37 (1.6)98 (2.85)59 (2.38)0 (0)0.0056HPV514 (1.21)7 (0.86)18 (1.45)105 (5.03)155 (7.07)151 (6.54)257 (7.47)166 (6.69)0 (0)0.016HPV594 (1.21)10 (1.23)24 (1.94)31 (1.48)33 (1.51)38 (1.65)53 (1.54)45 (1.81)0 (0)0.0032HPV353 (0.91)11 (1.36)12 (0.97)31 (1.48)20 (0.91)20 (0.87)44 (1.28)32 (1.29)0 (0)0.0047HPV442 (0.6)2 (0.25)14 (1.13)26 (1.25)19 (0.87)28 (1.21)69 (2.01)47 (1.89)0 (0)0.0182HPV421 (0.3)2 (0.25)14 (1.13)9 (0.43)10 (0.46)10 (0.43)62 (1.8)29 (1.17)0 (0)0.0488HPV430 (0)1 (0.12)2 (0.16)4 (0.19)1 (0.05)8 (0.35)38 (1.1)11 (0.44)1 (11.11)0.0868Total3318101238208821922310344024839

Trends of single-type and multiple-type HPV infection rates {#Sec10}
-----------------------------------------------------------

Single HPV genotype infection was found to be the most common pattern (72.32%, 7717/10,670). The multiple genotype infection rate was 27.68% (2953/10,670). Single-type infection (72.32%) was more common than multiple-type infection (27.68%). And the most mixed infection included 9 genotypes(Table [3](#Tab3){ref-type="table"}). Table 3Single-type and Multiple-type HPV infection rate in District Zhoupu of Shanghai CityNumber (HPV subtype)InfectionInfection Rate(%)1 HPV subtype771772.322 HPV subtypes206519.353 HPV subtypes6105.724 HPV subtypes2031.95 HPV subtypes510.486 HPV subtypes130.127 HPV subtypes90.088 HPV subtypes10.019 HPV subtypes10.01

Secular trends of the number of HPV single-type infection and multiple-type infection were also calculated. We found that the HPV numbers of single-type infection and some of multiple-type (2--5,7) infection rates among women showed significant differences from 2011 to 2019 (all *P* \< 0.05, Table [4](#Tab4){ref-type="table"}). Table 4Secular trends in single-type and multiple-type HPV infection rates from 2011 to 2019Number of (HPV infection subtypes)2011,n(%)2012,n(%)2013,n(%)2014,n(%)2015,n(%)2016,n(%)2017,n(%)2018,n(%)2019,n(%)*P* value\
for trend1 HPV subtypes160 (69.87)417 (71.28)600 (70.18)1040 (70.51)1119 (71.78)1235 (73.91)1737 (71.48)1400 (75.39)9 (100)0.00342 HPV subtypes46 (20.09)128 (21.88)173 (20.23)309 (20.95)312 (20.01)291 (17.41)478 (19.67)328 (17.66)0 (0)0.00293 HPV subtypes14 (6.11)29 (4.96)53 (6.2)92 (6.24)82 (5.26)96 (5.75)146 (6.01)98 (5.28)0 (0)0.00364 HPV subtypes8 (3.49)6 (1.03)19 (2.22)22 (1.49)32 (2.05)42 (2.51)50 (2.06)24 (1.29)0 (0)0.00485 HPV subtypes0 (0)4 (0.68)6 (0.7)8 (0.54)11 (0.71)6 (0.36)10 (0.41)6 (0.32)0 (0)0.00336 HPV subtypes1 (0.44)1 (0.17)2 (0.23)2 (0.14)1 (0.06)0 (0)6 (0.25)0 (0)0 (0)0.05127 HPV subtypes0 (0)0 (0)1 (0.12)2 (0.14)2 (0.13)1 (0.06)2 (0.08)1 (0.05)0 (0)0.018 HPV subtypes0 (0)0 (0)1 (0.12)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)0.34349 HPV subtypes0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)1 (0.04)0 (0)0 (0)0.3434Total4621214179429763218345049283796190

Trend analysis stratified by 5-year age groups from 2011 to 2019 {#Sec11}
----------------------------------------------------------------

For women aged \< 55 years, the highest prevalence numbers occurred in 2017, and the prevalence rate decreased from then. Prevalence number of HPV was significantly higher in women aged 25--34 years in Fig. [1](#Fig1){ref-type="fig"}a, in contrast to women older than 65 years in Fig. [1](#Fig1){ref-type="fig"}c. Fig. 1Trend analysis stratified by 5-Year Age groups from 2011 to 2019. **a** prevalence numbers of women (\< 20, 20--24,25-29,30-34,35--39) **b** prevalence numbers of women (40--44,45-49,50-54,55-59,60--64) **c** prevalence numbers of women (65--69,70-74,75-79,80--84,≥85)

Secular trends of HPV infection rates of different ages were also calculated. We found that HPV positive rates among women aged \< 80 years also showed significant differences from 2011 to 2019 (all *P* \< 0.05, Table [5](#Tab5){ref-type="table"}). Table 5Secular trends of HPV infection rates of different ages from 2011 to 2019Age (years)2011,n(%)2012,n(%)2013,n(%)2014,n(%)2015,n(%)2016,n(%)2017,n(%)2018,n(%)2019,n(%)*P* value for trend\< 205 (1.08)9 (0.74)14 (0.78)17 (0.57)28 (0.87)32 (0.93)41 (0.83)31 (0.82)0 (0)0.002920--2431 (6.71)64 (5.27)96 (5.35)156 (5.24)174 (5.41)192 (5.57)278 (5.64)249 (6.56)2 (11.11)0.002625--2951 (11.04)93 (7.66)151 (8.42)268 (9.01)301 (9.35)352 (10.2)546 (11.08)384 (10.12)1 (5.56)0.003930--3434 (7.36)101 (8.32)145 (8.08)201 (6.75)285 (8.86)313 (9.07)422 (8.56)329 (8.67)2 (11.11)0.002835--3928 (6.06)69 (5.68)116 (6.47)176 (5.91)189 (5.87)198 (5.74)320 (6.49)211 (5.56)1 (5.56)0.002640--4428 (6.06)78 (6.43)112 (6.24)165 (5.54)184 (5.72)183 (5.3)245 (4.97)171 (4.5)1 (5.56)0.001345--4926 (5.63)69 (5.68)92 (5.13)157 (5.28)141 (4.38)143 (4.14)215 (4.36)169 (4.45)0 (0)0.001450--54+16 (3.46)52 (4.28)76 (4.24)138 (4.64)136 (4.23)132 (3.83)187 (3.79)126 (3.32)1 (5.56)0.001855--599 (1.95)34 (2.8)47 (2.62)85 (2.86)88 (2.73)91 (2.64)95 (1.93)105 (2.77)1 (5.56)0.001660--642 (0.43)28 (2.31)27 (1.51)79 (2.65)52 (1.62)59 (1.71)66 (1.34)67 (1.77)0 (0)0.002465--691 (0.22)6 (0.49)13 (0.72)33 (1.11)22 (0.68)23 (0.67)38 (0.77)35 (0.92)0 (0)0.004770--740 (0)2 (0.16)6 (0.33)9 (0.3)5 (0.16)6 (0.17)6 (0.12)16 (0.42)0 (0)0.009975--790 (0)1 (0.08)2 (0.11)4 (0.13)4 (0.12)1 (0.03)3 (0.06)4 (0.11)0 (0)0.005780--840 (0)1 (0.08)0 (0)0 (0)0 (0)0 (0)1 (0.02)1 (0.03)0 (0)0.0805≥850 (0)0 (0)0 (0)0 (0)0 (0)0 (0)1 (0.02)0 (0)0 (0)0.3466Total4621214179429763218345049283796180

Discussion {#Sec12}
==========

Our study analyzed HPV prevalence trends of Zhoupu district in Shanghai city from 2011 to 2019. While the overall trend demonstrated there was an increase in prevalence rate, women aged \< 55 years in 2017 experienced the highest infection numbers, and a decline in HPV infection rate from 2018 to 2019. Zhoupu district is located in the suburb of Pudong New Area, Shanghai City of China. According to the analysis report of Pudong's population development in 2017 issued by the development and Reform Commission of Pudong New Area Government in Shanghai, there is a significant increase in the population development situation. So, the number of patients seeking medical treatment in the Zhoupu area also increases. The main reasons may be as follows: first, with the implementation of the two-children policy, the number and proportion of the two children have increased steadily; second, a large number of floating populations have gathered in the suburbs; third, the population ageing has deepened.

Single-type HPV infection and some of multiple-type (2--5,7) infection rates among women showed significant differences. HPV prevalence trends stratified by 5-year age groups demonstrated that HPV positive rates among women aged \< 80 years also showed significant differences.

In the 59,541 outpatient women, the overall prevalence of HPV was 17.92% and the HR-HPV prevalence was 15.56%. Compared with similar studies in China, the prevalence in our study was higher than that in Xinjiang (14.02%) \[[@CR11]\], Urumqi (16.74%) \[[@CR12]\], Zhejiang (17.6%) \[[@CR13]\], and Nanjing KingMed Diagnostics (17.7%) \[[@CR14]\], but lower than that in Meizhou (18.34%) \[[@CR15]\], Wuhan (18.6%) \[[@CR13]\], Beijing (20.16%) \[[@CR4]\], Guangdong (21.06%) \[[@CR16]\] Shandong (28.4%) \[[@CR17]\], and three cities (Xuzhou, Nanjing and Suzhou) of Jiangsu Province (26.92%) \[[@CR18]\]. Different HPV prevalence rates may be a combination of different economic levels, cultural diversity, geographic locations, and survey periods.

Analysis of HPV prevalence indicates that the most common HR-HPV genotypes in outpatient women are HPV 52,16,58,53 and 39. These are the same common genotypes as Meizhou \[[@CR15]\]. This is similar to other studies conducted in China. HPV 16,58, 52, 53, and 39 were the dominant subtypes in Jiangsu \[[@CR14]\]. HPV 52,16 and 58 had a higher prevalence in Beijing \[[@CR4]\]. HPV 52, 16, 58, CP8304, and 53 were the dominant subtypes among gynecological outpatients among women in Guangdong, China 2008 to 2017 \[[@CR16]\]. The most common HR-HPV group included HPV types 16, 31, 33, 35, 52, and 58 in Zhejiang and Wuhan \[[@CR13]\]. HPV 16, 52, 58, 51, and 56 were the five most common HR-HPV genotypes in Shandong \[[@CR17]\]. The most prevalent genotypes were HPV 16, 52,58,53 and 31 in Xinjiang \[[@CR11]\]. From the analysis of 303 China-specific articles, the top 4 common HPV types were detected HPV 16, 18, 58, 52 in descending order of frequency \[[@CR7]\]. The top 5 subtypes with the highest infection rates were 16, 52, 58, 53, and 18 in a systematic review of the epidemiology of HR-HPV infections in mainland Chinese women from January 2000 to June 2018 \[[@CR6]\]. Among all these studies above, HPV 52, 16 and 58 were the most common subtypes found, so vaccines against HPV 52, 16 and 58 should be developed for Chinese women.

Our research shows that HPV prevalence of women in Zhoupu District of Shanghai is age-related and single-type was more common than multiple-type HPV infection. The same is true in the rest of China, such as Guangdong and Beijing \[[@CR4], [@CR16]\]. Single-type was more common; however, multiple-type HPV infections are more dangerous than single-type infections. The HPV infection reached a peak in women aged 25--29 years. Perhaps because women in this age group are more sexually active and have more than one sexual partner, so HPV infection rates are higher than in other age groups. Our study may provide valuable data to inform cervical cancer screening and HPV vaccination programs for women in Shanghai.

Our research has an important policy implication: it is necessary to vaccinate Chinese women nationwide, especially young women, against HPV infection. Injecting HPV vaccine can induce a durable anti-HPV response and prevent HPV infection. At present, China has 2- and 4-valent HPV vaccines, and 9-valent vaccines in some regions (since May 2018). However, the proportion of women who are willing to take the initiative to receive the HPV vaccine is still very low, and various measures are urgently needed to increase the vaccination rate in China.

Our research focuses on the prevalence of HPV in different HPV-subtype-related and age-related groups, which allowed us to identify trends in differences in 2011--2019. However, our study also has some limitations. Although Zhoupu Hospital is the largest public hospital in the local area, it is located in the suburbs. These areas have large population mobility and relatively poor data quality.

In the future, we plan to examine the relationship between the mortality rate of cervical cancer and the HPV prevalence in Shanghai Zhoupu district. And we will compare it with the two databases from the World Health Organization Cancer Mortality Database (International Agency for Research on Cancer, Lyon, France) and China Health Statistical Yearbooks, like what Min did \[[@CR5]\].

Conclusions {#Sec13}
===========

In conclusion, we conducted a population-based study on the prevalence of HPV-subtype-related and age-related groups in the Zhoupu area of Shanghai. The cervical HPV prevalence rate is very high in younger women aged 25--34 years in suburb Shanghai city. The prevention of HPV-related diseases is challenging. There are significant differences in infection rates between specific age groups and HPV subtypes, and this finding will provide guidance for future vaccination programs and improve their accuracy.
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